Alnylam Seeks to Prove RNAi Skeptics Wrong After Layoffs, End of Novartis Deal

Those … who follow Cambridge, MA-based Alnylam Pharmaceuticals have come to expect the biotech to land major deals with large drug makers related to its gene-silencing drugs.
Xconomy